Advertisement

Annals of Hematology

, Volume 98, Issue 3, pp 793–795 | Cite as

Prominent regression of corneal crystalline deposits in multiple myeloma after treatment with proteasome inhibitor

  • Sayo Maeno
  • Shizuka KohEmail author
  • Michiko Ichii
  • Yoshinori Oie
  • Kohji Nishida
  • Yuzuru Kanakura
Letter to the Editor
  • 36 Downloads

Notes

Authors contribution

All authors contributed to patient management and to the writing of the report.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Written informed consent to publish personal information and case details has been obtained from the patient.

References

  1. 1.
    Milman T, Kao AA, Chu D, Gorski M, Steiner A, Simon CZ, Shih C, Aldave AJ, Eagle RC Jr, Jakobiec FA, Udell I (2015) Paraproteinemic keratopathy: the expanding diversity of clinical and pathologic manifestations. Ophthalmology 122:1748–1756CrossRefGoogle Scholar
  2. 2.
    Busch C, Koh S, Oie Y, Ichii M, Kanakura Y, Nishida K (2017) In vivo confocal microscopy of multiple myeloma associated crystalline keratopathy. Am J Hematol 92:593–594CrossRefGoogle Scholar
  3. 3.
    Kourelis TV, Nasr SH, Dispenzieri A, Kumar SK, Gertz MA, Fervenza FC, Buadi FK, Lacy MQ, Erickson SB, Cosio FG, Kapoor P, Lust JA, Hayman SR, Rajkumar V, Zeldenrust SR, Russell SJ, Dingli D, Lin Y, Gonsalves W, Lorenz EC, Zand L, Kyle RA, Leung N (2016) Outcomes of patients with renal monoclonal immunoglobulin deposition disease. Am J Hematol 91:1123–1128CrossRefGoogle Scholar
  4. 4.
    Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Blade J, Fermand JP, Hassoun H, Heffner L, Kukreti V, Vescio RA, Pei L, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL (2014) Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood 124:2498–2506CrossRefGoogle Scholar
  5. 5.
    Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, van de Donk NWCJ, Bruno B, Sezer O, Broijl A, Bringhen S, Beksac M, Larocca A, Hajek R, Musto P, Johnsen HE, Morabito F, Ludwig H, Cavo M, Einsele H, Sonneveld P, Dimopoulos MA, Palumbo A, on behalf of the European Myeloma Network (2015) European myeloma network guidelines for the management of multiple myeloma-related complications. Haematologica 100:1254–1266CrossRefGoogle Scholar
  6. 6.
    Buerk BM, Tu E (2002) Confocal microscopy in multiple myeloma crystalline keratopathy. Cornea 21:619–620CrossRefGoogle Scholar
  7. 7.
    Houben N, Foets B (2006) Confocal microscopy in multiple myeloma associated crystalline keratopathy: case report. Bull Soc Belg Ophthalmol 300:13–17Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of OphthalmologyOsaka University Graduate School of MedicineOsakaJapan
  2. 2.Department of Innovative Visual ScienceOsaka University Graduate School of MedicineSuitaJapan
  3. 3.Department of Hematology and OncologyOsaka University Graduate School of MedicineOsakaJapan

Personalised recommendations